Ad hoc: Carl Zeiss Meditec AG: Change in Management Board

Carl Zeiss Meditec AG / Board of directors / Ad hoc: Change in
Management Board

Ad hoc announcement according to §15 WpHG processed and transmitted
by Hugin. The issuer is solely responsible for the content of this
announcement.

----------------------------------------------------------------------
--------------

JENA - November 12, 2009.
After today's supervisory board meeting which ended at 2.44 pm, Carl
Zeiss Meditec AG (ISIN: DE0005313704) announces that in agreement
with the Supervisory and Management Boards its board member Bernd
Hirsch will resign from the Management Board effective November 30,
2009. Mr Hirsch is responsible for Finance and Controlling, Investor
Relations, Legal and Taxes, as well as Business Process Excellence.
He is leaving the company on his own accord to take up a new
challenge outside the Carl Zeiss Group.
The Supervisory Board thanks Mr Hirsch for his dedicated and
successful work in the Executive Board of Carl Zeiss Meditec.
The company will be announcing details of his successor in the near
future.
In the interim his duties will be taken over temporarily by board
members Dr. Michael Kaschke, Dr. Ludwin Monz and Ulrich Krauss.
In the financial year 2008/2009 the company exceeded the given
forecast. Carl Zeiss Meditec will be publishing its annual financial
statements on December 14, 2009.
Press contacts:
Eva Sesselmann
Corporate Communications
Carl Zeiss Meditec AG
07745 Jena, Germany
Phone: +49 3641 220-331
Fax: +49 3641 220-112
E-mail: press@meditec.zeiss.com

Patrick Kofler
Investor Relations
Carl Zeiss Meditec AG
07745 Jena, Germany
Phone: +49 3641 220-106
Fax: +49 3641 220-117
E-mail: investors@meditec.zeiss.com

Brief profile
Carl Zeiss Meditec AG (ISIN: DE 0005313704) is one of the world's
leading medical technology companies. The company supplies innovative
technologies and application-oriented solutions designed to help
doctors improve the quality of life of their patients. It provides
complete packages of solutions for the diagnosis and treatment of eye
diseases - including implants and consumable materials. The company
creates innovative visualisation solutions in the field of
microsurgery. Carl Zeiss Meditec's medical technology portfolio is
rounded off by promising future technologies such as intraoperative
radiation therapy.

In the 2007/2008 (30 September) financial year the 2,100 employees
generated sales of about ¤ 600 million. The head office of Carl Zeiss
Meditec is in Jena, Germany. The company has subsidiaries in Germany
and abroad; more than 50 percent of its employees are based in the
USA, Japan, Spain and France.

35 percent of Carl Zeiss Meditec shares are in free float. The
remaining 65 percent are held by Carl Zeiss AG, one of the world's
leading groups in the optical and opto-electronics industry. The five
independently managed business units of Carl Zeiss AG operate in the
future-oriented markets of "Medical and Research Solutions",
"Industrial Solutions" and "Lifestyle Products". The head office of
Carl Zeiss AG is in Oberkochen, Germany. In the 2007/08 financial
year (balance sheet date 30 September) the group posted sales of
¤ 2.7 billion. Carl Zeiss has a total workforce of about 13,000 in
over 30 countries, over 8,000 of them in Germany.

Further information: www.meditec.zeiss.com

--- End of Message ---

Carl Zeiss Meditec AG
Goeschwitzer Strasse 51-52 Jena Germany

WKN:
531370; ISIN: DE0005313704; Index: Prime All Share, TECH All Share,
TecDAX;
Listed: Freiverkehr in Bayerische Börse München, Freiverkehr in Börse
Stuttgart,
Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr
in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse, Regulierter Markt in
Frankfurter Wertpapierbörse;
Copyright © Hugin AS 2009. All rights reserved.